The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (interstitial lung disease/ILD)
Publications
A 66-year-old man with hydroxycarbamide induced pneumonitis.
The Netherlands journal of medicine. 2018;76(6):298-301
Hydroxyurea-Induced Interstitial Pneumonitis: A Rare Clinical Entity.
Kansas journal of medicine. 2017;10(2):47-49
[Hydroxyurea-induced pneumonia].
Revue des maladies respiratoires. 2014;31(5):430-4
Hydroxyurea-induced interstitial pneumonitis: case report and review of the literature.
European review for medical and pharmacological sciences. 2014;18(2):190-3
[Hydrocycarbamide induced fever: four cases and literature review].
La Revue de medecine interne. 2015;36(2):73-7
Hydroxyurea-induced pneumonitis in a patient with chronic idiopathic myelofibrosis after prolonged drug exposure.
European journal of haematology. 2003;71(5):388-90
[Hydroxyurea-induced pneumonitis].
Medizinische Klinik (Munich, Germany : 1983). 2003;98(7):394-7
Hydroxyurea-induced hypersensitivity pneumonitis: A case report and literature review.
Canadian respiratory journal. 2000;7(6):491-5
Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.
Annals of hematology. 1999;78(4):187-8
Recurrent pyrexia, cough and dyspnoea with hydroxyurea.
Australian and New Zealand journal of medicine. 1998;28(3):347
Hydroxyurea-induced acute alveolitis in a patient with chronic myeloid leukaemia.
Cancer chemotherapy and pharmacology. 1990;27(2):168-9